Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Joshua Hilton used to have two takeaways a night and weigh 20 stone. Now, inspired by his friend Sarah Jane Clark, the pair ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

For the uninitiated, the alphabet BBL might draw a blank. Not so for aspiring and practising socialites in our big capital ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...

These also allow application of weight loss therapies to be applied early and optimally," added Dr. Anoop Misra, Executive Chairman & Director of Diabetes and Endocrinology at Fortis C-DOC ...